NEW YORK (GenomeWeb) – Luminex announced today it has licensed the Xtreme Chain Reaction nucleic acid amplification technology from XCR Diagnostics.

The XCR technology enables rapid thermal cycling protocols in order to reduce assay turnaround times compared to traditional PCR.

"We look forward to leveraging the benefits that the XCR technology can bring to our future molecular diagnostics portfolio," Luminex President and CEO Homi Shamir said in a statement.

Financial terms for the non-exclusive, worldwide licensing agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.